Sign in

Trial result ·

Eltrombopag Added to Standard Immunosuppressive Treatment as Front-Line Therapy for Severe Aplastic Anemia: Long-Term Outcomes of the Phase-3 Randomized Superiority EBMT-SAAWP RACE Study.

Written based on 1 research study on PubMed, searched on 13 Nov 2026.

What was studied

This study looked at people with severe aplastic anemia. None of them had been treated for it before. In a phase 3 trial, people were put into groups by chance. One group of 101 people got the usual drugs that calm the immune system. These were horse antithymocyte globulin (hATG) and cyclosporine A. The other group of 96 people got the same drugs plus eltrombopag. This report gives the final results after 2 years.

What they found

People were followed for a median of 23.2 months. A full response to the drugs was clearly more common with eltrombopag. Living free of disease was also more common in that group. So was living free of other bad events. Overall survival was higher with eltrombopag. But this survival gap was not clear by the usual tests. Relapse rates were alike in both groups. Clinical PNH (paroxysmal nocturnal hemoglobinuria) showed up in fewer people given eltrombopag. Chromosome changes were rare in both groups.

What it means for patients

The authors say eltrombopag gave a better early blood response. They link this to better survival at 2 years. They also link it to more people living free of disease and events. They saw no higher risk of later myeloid blood cancers. In this trial, eltrombopag began on day 14 and ran up to 6 months.

Why it is not certain yet

The results only cover 2 years, so later effects are not known. The survival gain was not clear by the usual tests. The abstract does not give side effects in detail. Only people not treated before took part.

Source

Eltrombopag Added to Standard Immunosuppressive Treatment as Front-Line Therapy for Severe Aplastic Anemia: Long-Term Outcomes of the Phase-3 Randomized Superiority EBMT-SAAWP RACE Study.

PubMed · PMID 42472670

We restate facts from the source record in our own words. The original wording belongs to its publisher.

This page is not medical advice. Talk to your doctor about your own care.

Back to Aplastic anaemia publications